ACM
ENGNW icon

Atalaya Capital Management’s enGene Therapeutics Warrants ENGNW Stock Holding History

Atalaya Capital Management’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-66,666
Closed -$347K – 95
2024
Q1 		$347K Hold
66,666
– – 0.41% 20
2023
Q4 		$56.7K Buy
+66,666
New +$51.2K 0.08% 32

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Atalaya Capital Management's ENGNW Position: Q2 2024 in Review

Atalaya Capital Management sold out of enGene Therapeutics Warrants (ENGNW) in Q2 2024, closing a stake of 66,666 shares — an estimated $347K sold.

Atalaya Capital Management first reported a position in ENGNW in Q4 2023 and held it in 2 quarters. The position peaked at $347K in Q1 2024. 16 funds tracked by Wall St. Rank hold ENGNW as of Q2 2024.

  • Atalaya Capital Management reported no remaining enGene Therapeutics Warrants position as of Q2 2024 after selling out during the quarter.
  • Atalaya Capital Management sold 66,666 enGene Therapeutics Warrants shares in Q2 2024, an estimated $347K.
  • Atalaya Capital Management first reported a position in enGene Therapeutics Warrants in Q4 2023 and held it in 2 quarters.
  • Atalaya Capital Management's enGene Therapeutics Warrants position peaked at $347K in Q1 2024.
  • 16 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q2 2024.

Based on Atalaya Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.